Senate passes tax bill that repeals individual mandate

Lawmakers will now attempt to work out the differences between the Senate bill and a similar tax bill the House passed last month that preserves the mandate.

By David Lim • Dec. 2, 2017

PhRMA, Express Scripts go head to head on drug pricing

The industry group and the PBM are both being blamed for the high price of drugs, but a complex pricing system only muddies the waters more. 

By Lisa LaMotta • Nov. 30, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Sanofi to propose limits on use of dengue vaccine after safety signal

Recently analyzed clinical data showed the shot could intensify subsequent cases of the disease for individuals who had not previously been infected.

By Ned Pagliarulo • Nov. 30, 2017

FDA's generics goals may spell trouble for branded drug-device combos

With an eye to drug pricing, agency head Scott Gottlieb said the FDA is taking "taking new steps" to finalize guidance for generic drug-device combos.

By Jacob Bell • Nov. 29, 2017

FDA knocks generic maker for misbranding sleep aid

The warning letter to Magna Pharmaceuticals is only the third such notice issued this year by the FDA office in charge of regulating prescription drug promotion.

By Ned Pagliarulo • Nov. 29, 2017

Viagra comes out from behind the counter in the UK

The U.K. is the first country to permit Pfizer's Viagra to be sold in pharmacies without a prescription, a move aimed at curtailing the online black market.

By Suzanne Elvidge • Nov. 29, 2017

Biopharma in charts: New drugs and the search for growth

Threatened by competition to top-selling medicines, drugmakers across the industry are turning to new products. BioPharma Dive takes a look at how the efforts of seven biopharmas have fared. 

By Ned Pagliarulo • Nov. 28, 2017

How Anthem's new PBM will impact pharma

David Henka, CEO of RxTE Health, sat down with BioPharma Dive to discuss the implications of a new pharmacy benefit manager entering the marketplace. 

By Jacob Bell • Nov. 28, 2017

J&J eyes broader market for blood cancer med Darzalex

New study results could support approval of Darzalex in combination with three other drugs as a first-line treatment for certain patients with multiple myeloma.

By Ned Pagliarulo • Nov. 22, 2017

Concordia faces fine for bad pricing behavior

A U.K. regulator accused the drugmaker of price gouging, citing a near-6,000% increase in the price of a generic thyroid drug over 10 years.

By Suzanne Elvidge • Nov. 22, 2017

GSK boosted by US approval of two-drug HIV pill

Combining Tivicay with J&J's Edurant, the new regimen offers patients a less burdensome treatment option than current combos of three or more drugs. 

By Ned Pagliarulo • Nov. 22, 2017

Optum gets caught up in Express Scripts, Anthem legal fight

The latest legal challenge pulls Optum into an ongoing battle that adds turmoil to a rapidly changing and consolidating space.   

By Les Masterson • Nov. 21, 2017

Novo Nordisk: Obesity should be considered a chronic disease

Shifting dynamics in the diabetes market are pushing the Danish drugmaker to pursue other therapeutic areas. 

By Lisa LaMotta • Nov. 21, 2017

FDA pushes for more abuse-deterrent opioid generics

Under new Commissioner Gottlieb, the FDA has been looking to increase competition across markets by ushering more drugs through the system more efficiently. 

By Jacob Bell • Nov. 21, 2017

Roche's emicizumab wins US approval, threatening shake-up for hemophilia market

Hemlibra, as the drug will be marketed, is OK'd for routine prophylaxis in patients who have hemophilia A with factor VIII inhibitors.

By Jacob Bell • Nov. 16, 2017

Novartis sets Cosentyx hopes higher

Already a blockbuster, Cosentyx has been one of Novartis' fastest launches. Even so, the Swiss pharma believes more growth is in the cards.

By Ned Pagliarulo • Nov. 15, 2017

Boehringer wins EU approval for Humira biosimilar

Cyltezo won't launch in Europe until October 2018 at the earliest, but that still could be years before it enters the U.S. market due to litigation with AbbVie.

By Suzanne Elvidge • Nov. 15, 2017

AstraZeneca wins US approval for asthma biologic

The British drugmaker, long a leader in respiratory disease, has turned to biologics like Fasenra to fuel growth over the next decade.

By Ned Pagliarulo • Nov. 15, 2017

Amazon tells regulators it will not sell drugs

The e-commerce giant reportedly told Indiana and Tennessee regulators it would sell medical supplies from its new healthcare distribution centers.

By Edwin Lopez • Nov. 15, 2017

Digital Abilify pill secures first-of-its-kind FDA approval

Abilify MyCite embeds a sensor within a pill, and pairs the combo with a wearable patch, in order to help patients stay on regimen.

By Jacob Bell • Nov. 14, 2017

Hospitals file lawsuit to block 340B drug payment cut

Plaintiffs including the AHA argue the reimbursement change exceeds the authority of the HHS secretary and is "arbitrary and capricious."

By Shannon Muchmore • Nov. 14, 2017

Novo cuts more jobs in commercial restructuring

Increased competition and higher pricing pressures have hurt the Danish drugmaker in its core diabetes business.

By Lisa LaMotta • Nov. 13, 2017

Anthem reverses course, agrees to cover Sarepta's Duchenne drug

The insurer had originally decided last October against covering Exondys 51, citing the drug's mixed clinical evidence. 

By Suzanne Elvidge • Nov. 13, 2017

Ocrevus, Mvasi and 8 other drugs get CHMP go-ahead

The EMA advisory committee's latest approval recommendations included copycat and generic offerings that could sap money from blockbuster franchises.

By Jacob Bell • Nov. 10, 2017

Analysts fret over MannKind's disappearing cash

The inhalable insulin maker continues to struggle to commercialize its only product, putting a squeeze on the company's cash holdings. 

By Lisa LaMotta • Nov. 8, 2017